Clearance Summary
BNA Platform received FDA 510(k) clearance under submission number K202588, sponsored by Elminda, Ltd.. The device was reviewed via the Traditional premarket notification pathway and assigned to the Neurology review panel. The statutory decision date of record is 2020-12-07.
- Submission: K202588
- Applicant / Sponsor: Elminda, Ltd.
- Clearance pathway: Traditional
- Review panel: Neurology
- Device class: Class II
- Regulation citation: 21 CFR 882.1400
- Decision date: 2020-12-07
Classification & Regulation
This clearance is catalogued under FDA product code OLU and 21 CFR 882.1400, within the Neurology review panel as a Class II device.